HongShan

What HongShan does

HongShan (红杉) is a China-headquartered venture capital and private equity firm founded in 2005 and formerly known as Sequoia China. The firm invests across the technology, healthcare, and consumer sectors with a full-cycle strategy spanning seed (via the YUE Accelerator), early-stage venture, growth, M&A/buyout, infrastructure, and public market investments (via HCEP Management Limited, an SFC-licensed Type 9 manager). Headquartered in Wuhan with operational offices in Hong Kong, Beijing, Shanghai, and Shenzhen, HongShan reports a portfolio of 1,700+ companies, 180+ IPOs, and 140+ unicorns.

The firm's core products are investment vehicles rather than software platforms. HongShan Value+ is a six-module post-investment support system covering human capital, incubation, digital transformation, capital markets, brand activities, and events, operated with an investment-to-support staffing ratio of roughly 1:2. The YUE Accelerator deploys 7 million RMB pre-seed tickets with an eight-module mentorship curriculum. Specialized incubators include the Intelligent Healthcare Accelerator in Beijing/Shanghai and the Brain Science Incubator. The firm also publishes an annual Enterprise Digitalization Guide covering AIGC and organizational transformation.

HongShan generates revenue through traditional venture capital fund management economics: management fees charged on committed/deployed capital across multiple fund vintages, plus carried interest on exits. Strategic moves in 2024-2026 indicate an evolution from minority venture investing toward larger control-oriented deals in international consumer brands (Marshall Group at €1.1B, Golden Goose), complemented by continued exposure to autonomous driving (Pony.ai NASDAQ IPO), humanoid robotics (Unitree, X Square Robot), and life sciences (Bei Chen Sheng Ming STAR Market listing).

Name

HongShan

Legal name

武汉红杉桓夏科技有限公司

Website

https://hongshan.com

Company type

Private

Founded year

2005

Operating status

Operating

Short description

HongShan is a China-based venture capital and private equity firm founded in 2005 (formerly Sequoia China) investing across technology, healthcare, and consumer sectors at seed, growth, M&A, and public market stages. Its 1,700+ portfolio has produced 180+ IPOs and 140+ unicorns.

Ownership category

akta.pro rank

Product category

Venture Capital and Private Equity

NAICS

Other Financial Investment Activities (5239), All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (52394)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Geography-Focused Venture Capital (Regional/Emerging Markets) (FSANAAAE)

akta.pro secondary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital
• Private equity
• Growth investments
• Portfolio management
• Startup funding

Headquarters

HQ city

Pacific Palisades

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Venture Capital Fund Management: Management fees and carried interest from managing multiple VC funds across seed, early-stage, growth, M&A, and infrastructure investments

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

HongShan is a venture capital and private equity firm that deploys capital across seed, early-stage, growth, buyout, infrastructure, and public market stages, primarily into technology, healthcare, and consumer companies. The firm also operates the YUE startup accelerator (offering 7 million RMB seed funding) and HongShan Value+, a six-module post-investment support platform covering human capital, incubation, digitalization, capital markets, branding, and events for its 1,700+ portfolio companies.

Product overview

HongShan (红杉中国) is a venture capital and private equity firm offering investment services across seed, early-stage, growth, and public market stages. The firm's core products include HongShan Value+, a comprehensive post-investment support platform with 6 modules (human capital, incubation, digitalization, brand, events, capital markets), and YUE Accelerator, an early-stage startup accelerator providing 7 million RMB seed investment and 8-module mentorship. Additional offerings include the HongShan Intelligent Healthcare Accelerator, annual Enterprise Digitalization Guides as research publications, the HCEP public markets fund, and the HongShan Charity Foundation for philanthropy. HongShan has invested in over 1700 companies across technology, healthcare, and consumer sectors since 2005.

Differentiator

Problem solved

Functional benefit

Brands

• YUE: YUE创业加速器 (YUE Startup Accelerator) - an early-stage startup accelerator program offering 7 million RMB or equivalent USD investment, mentorship, and access to HongShan's 1,500+ portfolio companies network.
• HongShan Value+
• HCEP

Quantifiable outcome

• 180+ portfolio companies successfully IPO'd
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Wuhan HongShan Hengxia Technology Co., Ltd.minorOthersEntity maintaining and operating the HongShan website and providing operational services to HongShan China entities.

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

Emerging players

• Y Combinator: While YC operates a different model (global pre-seed accelerator) than HongShan's full-cycle VC platform, it competes at the earliest stage for high-quality startup founders and has expanded its China engagement via cross-border accelerator programs.

Broad incumbents

• General Atlantic: Global growth equity firm with significant Asia-Pacific presence, investing in technology, consumer, and healthcare growth-stage companies. Comparable at the growth-stage end of HongShan's range and as a competitor for international expansion deals (e.g., Marshall Group type transactions).
• Yunfeng Capital: Chinese private equity and venture platform founded by Jack Ma, investing broadly in tech, healthcare, and consumer. While newer and broader in mandate, Yunfeng operates in the same deal-competitive universe for premium Chinese growth and venture deals.

Direct peers

• Hillhouse Investment: One of the largest Asia-Pacific focused private equity and venture capital platforms, spanning early-stage venture to growth equity and public markets, with deep tech, consumer, and healthcare coverage. Direct competitor for top Chinese deal flow and LP capital alongside HongShan.
• Source Code Capital: China-focused venture capital firm founded by a Sequoia China alumnus, investing in technology, consumer, and enterprise software. A spin-out peer reflecting overlap with HongShan's sector coverage and founder network.
• Sequoia Capital: Sister firm to HongShan (formerly Sequoia China) before the 2024-2025 geographic split. Both operate as multi-stage venture and growth investors targeting technology, healthcare, and consumer opportunities with global founder networks. HongShan's rebrand explicitly distanced from Sequoia, but operating model and sector coverage remain directly comparable.
• Legend Capital: Pan-Asia venture and growth equity firm with significant Chinese deal flow across tech, healthcare, and consumer. Comparable to HongShan in stage coverage (early through growth) and sector breadth.
• GGV Capital: Multi-stage venture firm with strong China presence investing in technology, consumer, and enterprise sectors. Directly comparable in targeting Chinese founders with global ambitions, similar to HongShan's portfolio strategy.
• MatrixPartners China: China-focused venture capital firm investing across consumer, technology, and enterprise sectors. A direct competitor in early-stage Chinese tech deals with comparable fund size and LP base.
• IDG Capital: Long-standing China-focused venture and growth investor with broad sector coverage including tech, consumer, and healthcare. Competes with HongShan for early-stage and growth deals across Chinese startups and has comparable scale and institutional track record.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments39 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HongShan